In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|September 17, 2021
Moderna Releases New Clinical Data on COVID-19 Vaccine
Author(s)BioPharm International Editors
Moderna’s newest insights include an overall efficacy review, a study on breakthrough infections, and a study on long-term immunity.
Advertisement
Moderna released an analysis surrounding several studies on their COVID-19 vaccine on Sept. 15, 2021. In it, the company shared data surrounding the efficacy of the vaccine amidst the Delta variant surge, the risk of breakthrough infections, and the need for booster shots.
According to Moderna, a prospective cohort study of 352,878 recipients found that there was a vaccine effectiveness of 87% against COVID-19 diagnosis and 96% against COVID-19 hospitalization. The study was conducted during the emergence of the Delta variant, which was identified in 47% of cases in fully vaccinated individuals.
Moderna also did an analysis of data provided by CDC on breakthrough infections among individuals who received the vaccine. They found that their COVID-19 vaccine provided 92% efficacy against COVID-19 urgent care or emergency visit at a median of 96 days post-vaccination, and 95% efficacy against hospitalization at a median of 106 days after hospitalization.
In the Coronavirus Efficacy and Safety Study (COVE) study, an analysis comparing individuals vaccinated between July and October of 2020 and December 2020 and March of 2021, 88 breakthrough cases of COVID-19 occurred in the more recently vaccinated group (49.0 cases per 1000 people) compared to 162 cases in the group vaccinated last year (77.1 cases per 1000 people). Moderna believes that the impact of waning immunity provides evidence of the potential benefit of a booster dose of mRNA-1273.
“It is promising to see clinical and real-world evidence adding to the growing body of data on the effectiveness of the Moderna COVID-19 vaccine,” said Stéphane Bancel, CEO of Moderna, in a company press release. “The increased risk of breakthrough infections in COVE study participants who were vaccinated last year compared to more recently illustrates the impact of waning immunity and supports the need for a booster to maintain high levels of protection. We hope these findings are helpful as health authorities and regulators continue to assess strategies for ending this pandemic.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
ImvivaBio’s off-the-shelf CD19/BCMA CAR-T cell therapy CTA313 kept 88% of evaluable patients with refractory lupus in DORIS remission at Month 12, according to longer-term phase 1 data presented at ACR Convergence 2026.
Full phase 3 OASIZ-301 results show both dosing regimens of Amgen’s CD40L antagonist fusion protein dazodalibep reduced systemic disease activity in Sjögren’s disease at Week 48. The every-four-weeks dose also improved patient-reported dryness.
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5